Capital Research Global Investors
OREX

Capital Research Global Investors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Capital Research Global Investors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-362,000
Closed -$28.3M – 464
2015
Q1 		$28.3M Sell
362,000
-230,449
-39% -$14.3M 0.01% 389
2014
Q4 		$35.9M Sell
592,449
-197,106
-25% -$9.9M 0.01% 367
2014
Q3 		$33.6M Sell
789,555
-176,375
-18% -$9.47M 0.01% 367
2014
Q2 		$59.7M Sell
965,930
-82,500
-8% -$4.8M 0.02% 334
2014
Q1 		$68.1M Sell
1,048,430
-193,400
-16% -$13.1M 0.02% 315
2013
Q4 		$69.9M Buy
1,241,830
+384,330
+45% +$21.6M 0.03% 305
2013
Q3 		$52.7M Hold
857,500
– – 0.02% 333
2013
Q2 		$50.2M Buy
+857,500
New +$52.8M 0.02% 320

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Capital Research Global Investors's OREX Position: Q2 2015 in Review

Capital Research Global Investors sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 362,000 shares — an estimated $28.3M sold.

Capital Research Global Investors first reported a position in OREX in Q2 2013 and held it in 8 quarters. The position peaked at $69.9M in Q4 2013. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • Capital Research Global Investors reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Capital Research Global Investors sold 362,000 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $28.3M.
  • Capital Research Global Investors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 8 quarters.
  • Capital Research Global Investors's Orexigen Therapeutics, Inc. position peaked at $69.9M in Q4 2013.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Capital Research Global Investors's 13F filing for Q2 2015, filed 14 Aug 2015.